1. Indications and Usage
\nSchizophrenia:
\nTreatment of schizophrenia in adults and pediatric patients 13 to 17 years of age.
\nBipolar Depression:
\nTreatment of depressive episodes associated with Bipolar I Disorder (monotherapy or adjunctive with lithium or valproate) in adults and pediatric patients 10 to 17 years of age.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nSchizophrenia (Adults):
\nStarting Dose: 40 mg once daily.
\nMaintenance: 40 mg to 120 mg once daily.
\nMaximum: 120 mg once daily.
\nBipolar Depression (Adults):
\nStarting Dose: 20 mg once daily.
\nMaintenance: 20 mg to 120 mg once daily.
\nCritical Administration Instruction:
\nMUST BE TAKEN WITH FOOD: Must be taken with food (at least 350 calories). Taking with food significantly increases absorption (bioavailability).
\nDosing Time:
\nAdminister once daily at the same time each day (morning or evening).
\n3. Mechanism of Action
\nReceptor Profile:
\nLurasidone binds with high affinity to dopamine D2 receptors and serotonin 5-HT2A receptors.
\nAgonist\/Antagonist Activity:
\nAntagonist: Acts as an antagonist at D2 and 5-HT2A receptors (reducing positive symptoms like hallucinations).
\nPartial Agonist: Acts as a partial agonist at 5-HT1A receptors (potentially improving negative symptoms and cognition).
\nAntagonist: Has high affinity for 5-HT7 receptors (blocking which is linked to antidepressant and cognitive effects).
\n4. Safety and Warnings
\nIncreased Mortality in Elderly with Dementia (Boxed Warning):
\nElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
\nSuicidal Thoughts and Behaviors:
\nMonitor for the emergence of suicidal ideation and behavior.
\nMetabolic Changes:
\nMonitor for hyperglycemia, dyslipidemia, and weight gain.
\nNeuroleptic Malignant Syndrome (NMS):
\nA potentially fatal reaction characterized by hyperpyrexia, muscle rigidity, and autonomic instability.
\nTardive Dyskinesia:
\nRisk of developing abnormal, involuntary movements, which may be irreversible.
\n5.Adverse Reactions
\nMost Common (Schizophrenia):
\nNausea, somnolence, akathisia (inner restlessness), and vomiting.
\nMost Common (Bipolar Depression):
\nSomnolence, nausea, akathisia, and vomiting.
\n6.Drug Interactions
\nCYP3A4 Substrate:
\nLurasidone is primarily metabolized by CYP3A4.
\nStrong CYP3A4 Inhibitors:
\nContraindicated (e.g., ketoconazole, clarithromycin, ritonavir) as they significantly increase lurasidone levels.
\nStrong CYP3A4 Inducers:
\nContraindicated (e.g., rifampin, carbamazepine, St. John’s wort) as they significantly decrease lurasidone levels.
\nModerate Inhibitors\/Inducers:
\nDose adjustments are necessary when used with moderate CYP3A4 inhibitors (e.g., diltiazem) or inducers (e.g., modafinil).
\n7.Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Lurasidone Hydrochloride.
\nAvailable Strength: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg tablets.
\nStorage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u201330\u00b0C (59\u201386\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u7f57\u8212\u8fbe \u00ae(Latuda\u00ae)
\nGeneric Name: Lurasidone Hydrochloride
\nStrength: 40 mg per tablet (calculated as C\u2082\u2088H\u2083\u2086N\u2084O\u2082S\u30fbHCl)
\nManufacturer: Bushu Pharmaceuticals Ltd. Kawagoe Factory
\nMarketing Authorization Holder: Sunovion Pharmaceuticals Inc. (Domestic filing entity: Sumitomo Dainippon Pharma (Suzhou) Co., Ltd.)
\nApproval Date in China: January 24, 2019
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 H20191009
\nStorage: Store in a tightly closed container at temperatures not exceeding 30\u00b0C (86\u00b0F). Protect from light and moisture. Refer to the package insert for detailed storage and handling instructions.<\/p>\n
Price&Cost:Contact Us now for the best price of Lurasidone Hydrochloride\uff08Latuda\uff09<\/p>\n","protected":false},"featured_media":4066,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-4065","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n